Assessing AbbVie: Insights From 17 Financial Analysts
Assessing AbbVie: Insights From 17 Financial Analysts
评估艾伯维公司：来自17位财务分析师的见解
The standing of AbbVie...AbbVie (NYSE:ABBV) underwent analysis by 17 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
艾伯维公司（纽交所：ABBV）在上个季度接受了17位分析师的分析，显示出从看好到看淡的观点多样性。
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
下表提供了分析师最近评级的简明概述，提供了过去30天内情绪变化的洞察，并与前几个月进行了比较，以便全面了解。
Analysts have set 12-month price targets for AbbVie, revealing an average target of $211.24, a high estimate of $231.00, and a low estimate of $191.00. This current average has increased by 0.55% from the previous average price target of $210.08.
分析师为艾伯维公司设定了12个月的价格目标，显示出平均目标为211.24美元，最高估计为231.00美元，最低估计为191.00美元。当前的平均值比之前的平均价格目标210.08美元增加了0.55%。
Diving into Analyst Ratings: An In-Depth Exploration
深入探讨分析师评级：分析师评级的深度探讨
The standing of AbbVie...
通过对近...
登录免费看全文
登录/注册
资讯热榜
更新时间